期刊文献+

^(99m)Tc-DTPA眼眶显像在甲状腺相关性眼病中的临床应用 被引量:6

Clinical value of ^(99m)Tc-DTPA orbital scan in thyroid associated ophthalmopathy
下载PDF
导出
摘要 目的评价99mTc-DTPA眼眶显像在甲状腺相关眼病(TAO)患者眼部炎性反应活动度中的临床应用价值。方法将26例TAO患者依据临床活动度评分(CAS)标准分为活动组16例、非活动组10例。另选14例正常志愿者作为对照组。静脉注射显像剂99mTc-DTPA30min后行眼眶平面及断层显像,采用勾画感兴趣区技术计算99mTc-DTPA眼眶与枕部摄取比值(UR)。结果活动组TAO患者眼眶UR均高于非活动组和正常对照组(均P<0.001);而非活动组TAO患者与正常人的眼眶UR比较,差异无统计学意义(P>0.05)。所有TAO患者的UR与其CAS呈线性正相关(rall=0.859,P<0.001)。结论99mTc-DTPA眼眶显像可帮助判断TAO炎性反应活动度,是一种很有发展前途的评价甲状腺相关性眼病眶周炎性活动的方法。 Objective To evaluate the value of ^99mTc-DTPA orbital SPECT/CT in thyroid associated ophthalmopathy(TAO). Methods Acording to the clinical activitY score(CAS) ,26 patients were divided into two groups:active group( AG, n = 16)and inactive group (IAG, n = 10). Fourteen volunteers were included as controls. Scintigraphic images were obtained after intravenous injection of ^99mTc-DTPA for 0.5 h. The images were analyzed by a technique for specifying region of interest. The mean uptake ratio of the bilateral orbits was calculated. Results The mean orbit uptake ratio was higher significantly in AG group than in IAG group and control group(P 〈0.001 ), but there was no statistics difference between IAG group and control group( P 〉 0.05 ). There was a linear positive correlation between the ratio and CAS in TAO patients. Conclusion ^99mTc-DTPA orbital SPECT/CT could be helpful for judging the active degree of TAO. ^99mTc-DTPA orbital SPECT is a promising method for estimating disease activity in the orbits of patients with TAO.
出处 《山西医科大学学报》 CAS 2009年第6期563-566,共4页 Journal of Shanxi Medical University
关键词 ~99mTc-DTPA 眼眶 甲状腺相关性眼病 SPECT/CT ^99mTc-DTPA orbit thyroid associated ophthalmopathy SPECT/CT
  • 相关文献

参考文献3

二级参考文献15

  • 1崔炯,王中心,杨芳.血清白介素6及其可溶性受体水平与Graves眼病活动性[J].中华内分泌代谢杂志,2004,20(3):244-245. 被引量:4
  • 2李玲,叶万忠,李建,陈侃,张春华,包建东.Graves眼病眶部生长抑素受体显像研究[J].中华核医学杂志,2005,25(3):166-167. 被引量:6
  • 3段炼,李险峰,胡光,张承刚,李思进.^(99)Tc^m-奥曲肽眼眶显像在甲状腺相关眼病中的初步应用[J].山西医科大学学报,2005,36(3):369-371. 被引量:1
  • 4Weetman AP. Graves' disease[J]. N Engl J Med,2000,343(17):1236-1248.
  • 5Gerding MN,van der Zant FM,van Royen EA,et al. Octreotidescintigraphy is a disease-activity parameter in Graves ophthalmopathy[J]. Clin Endocrinol (Oxf), 1999,50(3) :373-379.
  • 6Burggasser G, Hurtl I, Hauff W, et al. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves disease[J]. J Nucl Med,2003,44(10) :1547-1555.
  • 7Prummel MF. Graves' ophthalmopathy: diagnosis and management. Eur J Nucl Med, 2000, 27: 373-376.
  • 8Gerding MN, Van der Zant FM, Van Royen FA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol,1999, 50: 373-379.
  • 9Marcocci C,Marino M, Rocchi R, et al. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest, 2004, 27: 272-280.
  • 10Wemer SC. Modification of the classification of the eye change of Graves'disease: recommendation of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab, 1977, 44: 203-204.

共引文献22

同被引文献28

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部